RxDoctor Payments Data

Guy Mintz, MD

Cardiovascular Disease · Great Neck, NYNPI 1508869884

Payments from drug & device makers

$148,676in general payments, 2019–2025

Across 118 payments — averaging $1259.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$55K
  • Amgen$36K
  • Esperion Therapeutics, Inc.$18K
  • Johnson & Johnson$13K
  • Regeneron$6K
  • Novo Nordisk$6K
  • plus $15K from 10 others

What the payments were for

  • Consulting fees$29,10341%
  • Speaking & faculty fees$35,49850%
  • Travel & lodging$3,0634%
  • Food & beverage$3,5355%
  • Education$680%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$148,676 in reported general payments places this provider in the 90th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$667,482
Medicare patients
1,048
Services billed
19,283

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban167$217,626
Repatha SureclickEvolocumab172$192,392
EliquisApixaban107$125,320
Praluent PenAlirocumab62$59,716
OzempicSemaglutide23$35,344
Telmisartan-HydrochlorothiazidTelmisartan/Hydrochlorothiazid276$26,572
Ezetimibe744$23,485
Telmisartan719$20,970
NexlizetBempedoic Acid/Ezetimibe21$20,917
EntrestoSacubitril/Valsartan19$19,831
Rosuvastatin Calcium1,265$19,731
WegovySemaglutide12$15,299
VascepaIcosapent Ethyl16$14,176
NexletolBempedoic Acid17$13,960
Metoprolol Succinate526$8,826

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$12,844$217,626167 claims
Novo NordiskOzempic, Wegovy$6,200$50,64335 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$17,902$34,87638 claims
NovartisEntresto$55,140$19,83119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Great Neck

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →